AZD 8601

Drug Profile

AZD 8601

Alternative Names: AZD-8601

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca; Moderna Therapeutics
  • Developer AstraZeneca; Moderna Therapeutics; The Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre
  • Class Cardiovascular therapies; RNA; Small molecules
  • Mechanism of Action Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus
  • Preclinical Cardiovascular disorders; Metabolic disorders

Most Recent Events

  • 14 Sep 2017 Moderna Therapeutics submitted a clinical trial application in Europe for a phase IIa trial
  • 14 Sep 2017 Moderna Therapeutics plans a phase IIa trial for Cardiovascular disorders in Europe
  • 04 Aug 2017 Moderna Therapeutics completes a phase I trial in Type-2 diabetes mellitus in Germany (NCT02935712)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top